Serum adiponectin and bone mineral density in male hemodialysis patients

Osteoporosis International

Volumn 23, Issue 7, 2012, Pages 2027-2035

  Okuno, S ^a   Ishimura, E ^b   Norimine, K ^a   Tsuboniwa, N ^a   Kagitani, S ^a   Yamakawa, K ^a   Yamakawa, T ^a   Sato, K K ^b   Hayashi, T ^b   Shoji, S ^a   Nishizawa, Y ^b   Inaba, M ^b  

^a OSAKA CITY UNIVERSITY   (Japan)

^b OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Adiponectin; Bone markers density; Bone mineral; Hemodialysis

Indexed keywords

ADIPONECTIN; ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE;

ADULT; ARTICLE; BONE DENSITY; CANCELLOUS BONE; CHRONIC KIDNEY DISEASE; CORTICAL BONE; DIABETIC PATIENT; DISEASE ASSOCIATION; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; JAPANESE; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; OSTEOLYSIS; PRIORITY JOURNAL; RADIUS; STATISTICAL ANALYSIS; TREATMENT DURATION;

ABSORPTIOMETRY, PHOTON; ADIPONECTIN; AGED; BIOLOGICAL MARKERS; BODY COMPOSITION; BODY WEIGHT; BONE DENSITY; BONE REMODELING; BONE RESORPTION; HUMANS; KIDNEY FAILURE, CHRONIC; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; RADIUS; RENAL DIALYSIS;

EID: 84863563746     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-011-1789-5     Document Type: Article

References (50)

1. Yatagai T, Nagasaka S, Taniguchi A, Fukushima M, Nakamura T, Kuroe A, Nakai Y, Ishibashi S (2003) Hypoadiponectinemia is associated with visceral fat accumulation and insulin resistance in Japanese men with type 2 diabetes mellitus. Metabolism 52:1274-1278.
2. Lindsay RS, Funahashi T, Hanson RL, Matsuzawa Y, Tanaka S, Tataranni PA, Knowler WC, Krakoff J (2002) Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 360:57-58.
3. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y (1999) Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257:79-83.
4. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, Maeda K, Nishida M, Kihara S, Sakai N, Nakajima T, Hasegawa K, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Hanafusa T, Matsuzawa Y (2000) Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20:1595-1599.
5. Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, Hotta K, Nishida M, Takahashi M, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y (1999) Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 100:2473-2476.
6. Matsuzawa Y (2010) Establishment of a concept of visceral fat syndrome and discovery of adiponectin. Proc Jpn Acad Ser B Phys Biol Sci 86:131-141.
7. Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Cutrupi S, Parlongo S, Malatino LS, Bonanno G, Seminara G, Rapisarda F, Fatuzzo P, Buemi M, Nicocia G, Tanaka S, Ouchi N, Kihara S, Funahashi T, Matsuzawa Y (2002) Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 13:134-141.
8. Odamaki M, Furuya R, Kinumura Y, Ikegaya N, Kumagai H (2006) Association between plasma adiponectin concentration and visceral fat accumulation in hemodialysis patients. Nephron Clin Pract 102:c8-c13.
9. Ignacy W, Chudek J, Adamczak M, Funahashi T, Matsuzawa Y, Kokot F, Wiecek A (2005) Reciprocal association of plasma adiponectin and serum C-reactive protein concentration in haemodialysis patients with end-stage kidney disease-a followup study. Nephron Clin Pract 101:c18-c24.
10. Menon V, Li L, Wang X, Greene T, Balakrishnan V, Madero M, Pereira AA, Beck GJ, Kusek JW, Collins AJ, Levey AS, Sarnak MJ (2006) Adiponectin and mortality in patients with chronic kidney disease. J Am Soc Nephrol 17:2599-2606.
11. Rao M, Li L, Tighiouart H, Jaber BL, Pereira BJ, Balakrishnan VS (2008) Plasma adiponectin levels and clinical outcomes among haemodialysis patients. Nephrol Dial Transplant 23:2619-2628.
12. Diez JJ, Estrada P, Bajo MA, Fernandez-Reyes MJ, Grande C, del Peso G, Heras M, Molina A, Iglesias P, Sanchez-Villanueva R, Selgas R (2009) High stable serum adiponectin levels are associated with a better outcome in prevalent dialysis patients. Am J Nephrol 30:244-252.
13. Drechsler C, Krane V, Winkler K, Dekker FW, Wanner C (2009) Changes in adiponectin and the risk of sudden death, stroke, myocardial infarction, and mortality in hemodialysis patients. Kidney Int 76:567-575.
14. Ealey KN, Kaludjerovic J, Archer MC, Ward WE (2008) Adiponectin is a negative regulator of bone mineral and bone strength in growing mice. Exp Biol Med (Maywood) 233:1546-1553.
15. Berner HS, Lyngstadaas SP, Spahr A, Monjo M, Thommesen L, Drevon CA, Syversen U, Reseland JE (2004) Adiponectin and its receptors are expressed in bone-forming cells. Bone 35:842-849.
16. Kidney Disease: Improving Global Outcomes (KDIGO) CKDMBD Work Group (2009) KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int SUPPL. S1-130.
17. Nishizawa Y, Nakamura T, Ohata H, Kushida K, Gorai I, Shiraki M, Fukunaga M, Hosoi T, Miki T, Nakatsuka K, Miura M (2001) Guidelines on the use of biochemical markers of bone turnover in osteoporosis (2001). J Bone Miner Metab 19:338-344.
18. Delmas PD, Eastell R, Garnero P, Seibel MJ, Stepan J (2000) The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporos Int 11(SUPPL. 6): S2-S17.
19. Maeno Y, Inaba M, Okuno S, Yamakawa T, Ishimura E, Nishizawa Y (2005) Serum concentrations of cross-linked Ntelopeptides of type I collagen: new marker for bone resorption in hemodialysis patients. Clin Chem 51:2312-2317.
20. Ueda M, Inaba M, Okuno S, Maeno Y, Ishimura E, Yamakawa T, Nishizawa Y (2005) Serum BAP as the clinically useful marker for predicting BMD reduction in diabetic hemodialysis patients with low PTH. Life Sci 77:1130-1139.
21. Ueda M, Inaba M, Okuno S, Nagasue K, Kitatani K, Ishimura E, Shimizu M, Miki T, Kim M, Nishizawa Y (2002) Clinical usefulness of the serum N-terminal propeptide of type I collagen as a marker of bone formation in hemodialysis patients. Am J Kidney Dis 40:802-809.
22. Kanazawa I, Yamaguchi T, Yamamoto M, Yamauchi M, Yano S, Sugimoto T (2009) Relationships between serum adiponectin levels versus bone mineral density, bone metabolic markers, and vertebral fractures in type 2 diabetes mellitus. Eur J Endocrinol 160:265-273.
23. Jurimae J, Rembel K, Jurimae T, Rehand M (2005) Adiponectin is associated with bone mineral density in perimenopausal women. Horm Metab Res 37:297-302.
24. Lenchik L, Register TC, Hsu FC, Lohman K, Nicklas BJ, Freedman BI, Langefeld CD, Carr JJ, Bowden DW (2003) Adiponectin as a novel determinant of bone mineral density and visceral fat. Bone 33:646-651.
25. Peng XD, Xie H, Zhao Q, Wu XP, Sun ZQ, Liao EY (2008) Relationships between serum adiponectin, leptin, resistin, visfatin levels and bone mineral density, and bone biochemical markers in Chinese men. Clin Chim Acta 387:31-35.
26. Richards JB, Valdes AM, Burling K, Perks UC, Spector TD (2007) Serum adiponectin and bone mineral density in women. J Clin Endocrinol Metab 92:1517-1523.
27. Huang KC, Cheng WC, Yen RF, Tsai KS, Tai TY, Yang WS (2004) Lack of independent relationship between plasma adiponectin, leptin levels and bone density in nondiabetic female adolescents. Clin Endocrinol (Oxf) 61:204-208.
28. Jurimae J, Jurimae T (2007) Plasma adiponectin concentration in healthy pre-and postmenopausal women: relationship with body composition, bone mineral, and metabolic variables. Am J Physiol Endocrinol Metab 293:E42-E47.
29. Oh KW, Lee WY, Rhee EJ, Baek KH, Yoon KH, Kang MI, Yun EJ, Park CY, Ihm SH, Choi MG, Yoo HJ, Park SW (2005) The relationship between serum resistin, leptin, adiponectin, ghrelin levels and bone mineral density in middle-aged men. Clin Endocrinol (Oxf) 63:131-138.
30. Kontogianni MD, Dafni UG, Routsias JG, Skopouli FN (2004) Blood leptin and adiponectin as possible mediators of the relation between fat mass and BMD in perimenopausal women. J Bone Miner Res 19:546-551.
31. Ozkurt B, Ozkurt ZN, Altay M, Aktekin CN, Caglayan O, Tabak Y (2009) The relationship between serum adiponectin level and anthropometry, bone mass, osteoporotic fracture risk in postmenopausal women. Eklem Hastalik Cerrahisi 20:78-84.
32. Bacchetta J, Boutroy S, Guebre-Egziabher F, Juillard L, Drai J, Pelletier S, Richard M, Charrie A, Carlier MC, Chapurlat R, Laville M, Fouque D (2009) The relationship between adipokines, osteocalcin and bone quality in chronic kidney disease. Nephrol Dial Transplant 24:3120-3125.
33. Guideline Working Group, Japanese Society for Dialysis Therapy (2008) Clinical practice guideline for the management of secondary hyperparathyroidism in chronic dialysis patients. Ther Apher Dial 12:514-525.
34. Okuno S, Inaba M, Kitatani K, Ishimura E, Yamakawa T, Nishizawa Y (2005) Serum levels of C-terminal telopeptide of type I collagen: a useful new marker of cortical bone loss in hemodialysis patients. Osteoporos Int 16:501-509.
35. Gomez B Jr, Ardakani S, Ju J, Jenkins D, Cerelli MJ, Daniloff GY, Kung VT (1995) Monoclonal antibody assay for measuring bone-specific alkaline phosphatase activity in serum. Clin Chem 41:1560-1566.
36. Kumeda Y, Inaba M, Tahara H, Kurioka Y, Ishikawa T, Morii H, Nishizawa Y (2000) Persistent increase in bone turnover in Graves' patients with subclinical hyperthyroidism. J Clin Endocrinol Metab 85:4157-4161.
37. Gertz BJ, Clemens JD, Holland SD, Yuan W, Greenspan S (1998) Application of a new serum assay for type I collagen cross-linked N-telopeptides: assessment of diurnal changes in bone turnover with and without alendronate treatment. Calcif Tissue Int 63:102-106.
38. Clemens JD, Herrick MV, Singer FR, Eyre DR (1997) Evidence that serum NTx (collagen-type I N-telopeptides) can act as an immunochemical marker of bone resorption. Clin Chem 43:2058-2063.
39. Baron R (1999) Anatomy and ultrastructure of bone. In: Fravus MJ (ed) Primer on the metabolic bone diseases and disorders of mineral metabolism. Lippincott Williams, Philadelphia, pp 3-10.
40. Kohno K, Inaba M, Okuno S, Maeno Y, Maekawa K, Yamakawa T, Ishimura E, Nishizawa Y (2009) Association of reduction in bone mineral density with mortality in male hemodialysis patients. Calcif Tissue Int 84:180-185.
41. Ishimura E, Okuno S, Kim M, Yamamoto T, Izumotani T, Otoshi T, Shoji T, Inaba M, Nishizawa Y (2001) Increasing body fat mass in the first year of hemodialysis. J Am Soc Nephrol 12:1921-1926.
42. Zhao LJ, Jiang H, Papasian CJ, Maulik D, Drees B, Hamilton J, Deng HW (2008) Correlation of obesity and osteoporosis: effect of fat mass on the determination of osteoporosis. J Bone Miner Res 23:17-29.
43. Frost M, Abrahamsen B, Nielsen TL, Frystyk J, Flyvbjerg A, Hagen C, Andersen M, Brixen K (2010) Adiponectin and peak bone mass in men: a cross-sectional, population-based study. Calcif Tissue Int 87:36-43.
44. Oshima K, Nampei A, Matsuda M, Iwaki M, Fukuhara A, Hashimoto J, Yoshikawa H, Shimomura I (2005) Adiponectin increased bone mass by suppressing osteoclast and actiating osteoblast. Biochem Biophys Res Commun 331:520-526.
45. Luo XH, Guo LJ, Yuan LQ, Xie H, Zhou HD, Wu XP, Liao EY (2005) Adiponectin stimulates human osteoblasts proliferation and differentiation via the MAPK signaling pathway. Exp Cell Res 309:99-109.
46. Luo XH, Guo LJ, Xie H, Yuan LQ, Wu XP, Zhou HD, Liao EY (2006) Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway. J Bone Miner Res 21:1648-1656
47. Wu N, Wang QP, Li H, Wu XP, Sun ZQ, Luo XH (2010) Relationships between serum adiponectin, leptin concentrations and bone mineral density, and bone biochemical markers in Chinese women. Clin Chim Acta 411:771-775.
48. Wolf G (2003) Adiponectin: a regulator of energy homeostasis. Nutr Rev 61:290-292.
49. Oh DK, Ciaraldi T, Henry RR (2007) Adiponectin in health and disease. Diabetes Obes metab 9:282-289.
50. Araneta MR, von Muhlen D, Barrett-Connor E (2009) Sex differences in the association between adiponectin and BMD, bone loss, and fractures: the Rancho Bernardo study. J Bone Miner Res 24:2016-2022